FI86854B - Foerfarande foer framstaellning av kristallina hydrat av cefalosporinsalt. - Google Patents
Foerfarande foer framstaellning av kristallina hydrat av cefalosporinsalt. Download PDFInfo
- Publication number
- FI86854B FI86854B FI890213A FI890213A FI86854B FI 86854 B FI86854 B FI 86854B FI 890213 A FI890213 A FI 890213A FI 890213 A FI890213 A FI 890213A FI 86854 B FI86854 B FI 86854B
- Authority
- FI
- Finland
- Prior art keywords
- methyl
- crystalline
- water
- salt
- zwitterion
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 23
- -1 alpha-(Z)-methoxyiminoacetamido Chemical group 0.000 claims abstract description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 150000004683 dihydrates Chemical class 0.000 claims description 7
- 150000004682 monohydrates Chemical class 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- CKQQMPJQZXIYMJ-UHFFFAOYSA-N dihydrate;dihydrochloride Chemical compound O.O.Cl.Cl CKQQMPJQZXIYMJ-UHFFFAOYSA-N 0.000 claims description 5
- 238000002441 X-ray diffraction Methods 0.000 claims description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 62
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract description 4
- 229960003646 lysine Drugs 0.000 abstract description 4
- 235000011007 phosphoric acid Nutrition 0.000 abstract description 3
- 239000012453 solvate Substances 0.000 abstract description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 46
- 238000007792 addition Methods 0.000 description 36
- 239000000203 mixture Substances 0.000 description 28
- 238000002425 crystallisation Methods 0.000 description 15
- 230000008025 crystallization Effects 0.000 description 15
- 239000002253 acid Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000003828 vacuum filtration Methods 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229930186147 Cephalosporin Natural products 0.000 description 5
- 229940124587 cephalosporin Drugs 0.000 description 5
- 238000000113 differential scanning calorimetry Methods 0.000 description 5
- 239000007972 injectable composition Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 238000002411 thermogravimetry Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000006069 physical mixture Substances 0.000 description 4
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229960004261 cefotaxime Drugs 0.000 description 2
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 2
- 229960000484 ceftazidime Drugs 0.000 description 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000694440 Colpidium aqueous Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical class OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
- C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (4)
1. Förfarande för framställning av ett kristallint dihydrokloridmonohydrat och -dlhydrat av 7-[a-(2-aminotia- 5 zol-4-yl)-a- ( Z ) -metoxiiminoacetamido] -3- [ (1-metyl-pyrroli- dinio)metyl]-3-cefem-4-karboxylat, känneteck-n a t därav, att (A) motsvarande zwitterjon omvandlas tili ett kristallint dihydrokloridmonohydrat medelst vat-tenhaltig klorvätesyra och aceton, varefter, (B) om s& 10 önskas, bildas ett kristallint dihydroklorid-dihydrat ge- nom hydratering av det sä erhällna monohydratet.
2. Förfarande enligt patentkravet 1, känne-t e c k n a t därav, att man framställer ett kristallint dihydrokloridhydrat av 7-[a-(2-aminotiazol-4-yl)-a-(Z)- 15 metoxiiminoacetamido]-3-[(1-metylpyrrolidinio)metyl]-3- cefem-4-karboxylat, som innehäller 2,5 - 7,0 vikt-% vat-ten.
3. Förfarande enligt patentkravet 1, känne-t e c k n a t därav, att man framställer ett kristallint 20 dihydroklorid-monohydrat av 7-[a-(2-aminotiazol-4-yl)-a- (Z)-metoxiiminoacetamido]-3-[(1-metylpyrrolidinio)metyl]- 3-cefem-4-karboxylat, som innehäller 2,5 - 4,1 vikt-% vetten.
4. Förfarande enligt patentkravet 1, känne- '-25 tecknat därav, att man framställer ett kristallint dihydroklorid-monohydrat av 7-[a-(2-aminotiazol-4-yl)-a-( Z)-metoxiiminoacetamido]-3-[(1-metylpyrrolidinio)metyl]- 3-cefem-4-karboxylat, som har följande röntgendiffrak-tionsvärden i pulverform: 30 20 86854 Röntgensträle-pulverdiffraktionsfördelning Dihydrokloridmonohydrat d I/IQ (%) 5 10,21 100 8.62 13 6.78 23 6,28 9 5,84 9 10 5,12 4 5,01 9 4.95 5 4,74 38 4.62 4 15 4,50 4 4,44 4 4,26 32 4, 10 4 3.95 33 20 3,90 28 3.78 39 3,64 5 3,59 13 3,48 10 25 3,39 15 3,32 10 3,21 10 3,11 10 3,04 5 30 2,99 13 2,93 15 2,76 5 2.63 10 2,51 10 35 2,43 5 2,38 7
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14489988 | 1988-01-19 | ||
| US07/144,899 US4910301A (en) | 1985-08-05 | 1988-01-19 | Cefepime cephalosporin salts |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI890213A0 FI890213A0 (fi) | 1989-01-16 |
| FI890213A FI890213A (fi) | 1989-07-20 |
| FI86854B true FI86854B (fi) | 1992-07-15 |
| FI86854C FI86854C (sv) | 1992-10-26 |
Family
ID=22510643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI890213A FI86854C (sv) | 1988-01-19 | 1989-01-16 | Förfarande för framställning av kristallina hydrat av cefalosporinsalt |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US4910301A (sv) |
| JP (1) | JPH0725768B2 (sv) |
| KR (1) | KR950003612B1 (sv) |
| AT (1) | AT399878B (sv) |
| AU (1) | AU615509B2 (sv) |
| BE (1) | BE1002749A5 (sv) |
| CA (1) | CA1298288C (sv) |
| CY (1) | CY1663A (sv) |
| CZ (1) | CZ281602B6 (sv) |
| DD (2) | DD283397A5 (sv) |
| DE (1) | DE3901359A1 (sv) |
| DK (1) | DK162054C (sv) |
| EG (1) | EG18749A (sv) |
| ES (1) | ES2012948A6 (sv) |
| FI (1) | FI86854C (sv) |
| FR (1) | FR2626003B1 (sv) |
| GB (1) | GB2213819B (sv) |
| GR (1) | GR1001218B (sv) |
| HK (1) | HK72292A (sv) |
| HU (1) | HU205940B (sv) |
| IE (1) | IE67447B1 (sv) |
| IT (1) | IT1229528B (sv) |
| LU (1) | LU87432A1 (sv) |
| NL (1) | NL192266C (sv) |
| NZ (1) | NZ227605A (sv) |
| OA (1) | OA09227A (sv) |
| PT (1) | PT89474B (sv) |
| SE (1) | SE505258C2 (sv) |
| SG (1) | SG75492G (sv) |
| SK (1) | SK281768B6 (sv) |
| YU (1) | YU221188A (sv) |
| ZA (1) | ZA89407B (sv) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5244891A (en) * | 1985-08-05 | 1993-09-14 | Bristol-Myers Squibb Company | Injectable compositions of cefepime dihydrochloride hydrate |
| EP0376185B1 (en) * | 1988-12-27 | 1994-08-17 | Chugai Seiyaku Kabushiki Kaisha | Process for purification of 1,2-bis(nicotinamido)propane |
| CA2011116C (en) * | 1989-03-06 | 1999-11-16 | Murray A. Kaplan | Lyophilized bmy-28142 dihydrochloride for parenteral use |
| DE3919259A1 (de) * | 1989-06-13 | 1990-12-20 | Hoechst Ag | Kristalline cephem-saeureadditionssalze und verfahren zu ihrer herstellung |
| US5594129A (en) * | 1991-09-10 | 1997-01-14 | Bristol-Myers Squibb Company | Process for the preparation of a cephalosporin antibiotic |
| YU81692A (sh) * | 1991-09-10 | 1995-03-27 | Bristol-Myers Co. | Postupak za proizvodnju cefalosporinskog antibiotika |
| US5698703A (en) * | 1991-09-10 | 1997-12-16 | Bristol-Myers Squibb Company | Syn-isomer of thiazolyl intermediate and process for the preparation thereof |
| MY108872A (en) * | 1991-09-10 | 1996-11-30 | Bristol Myers Squibb Co | Preparation of a cephalosporin antibiotic using the syn-isomer of a thiazolyl intermediate. |
| TW232695B (sv) * | 1992-07-24 | 1994-10-21 | Bristol Myers Squibb Co | |
| CA2101571A1 (en) * | 1992-09-08 | 1994-03-09 | Elizabeth A. Garofalo | Crystalline dihydrate of a cephalosporin dihydrate salt and injectable compositions thereof |
| US5391729A (en) * | 1992-09-08 | 1995-02-21 | Bristol-Myers Squibb Company | Crystalline dihydrate of a cephalosporin salt |
| US5401842A (en) * | 1992-09-08 | 1995-03-28 | Bristol-Myers Squibb Company | Injectable compositions of a cephalosporin dihydrate salt |
| JPH0840907A (ja) | 1994-08-03 | 1996-02-13 | Meiji Seika Kaisha Ltd | セファロスポリン注射剤 |
| WO2005094800A2 (en) * | 2004-03-31 | 2005-10-13 | Lupin Ltd. | A co-precipitated cefepime composition and process for preparation thereof |
| EP1773845A1 (en) * | 2004-07-16 | 2007-04-18 | Hetero Drugs Limited | Process for preparing pure cephalosporine intermediates |
| ITMI20051684A1 (it) * | 2005-09-13 | 2007-03-14 | Harvest Lodge Ltd | Procedimento per la produzione del dicloridrato di amminoacidi |
| ITMI20060422A1 (it) * | 2006-03-09 | 2007-09-10 | Harvest Lodge Ltd | Procedimento diretto per la produzione del dicloridrato di un amminoacido |
| US8151846B2 (en) * | 2006-12-15 | 2012-04-10 | Center Line Wheel Corporation | Wheel having inner bead-lock |
| AR077320A1 (es) * | 2009-07-20 | 2011-08-17 | Intervet Int Bv | Metodo para la preparacion de particulas de cefquinoma y formulaciones farmaceuticas que las comprenden. |
| CN103304580B (zh) * | 2013-06-09 | 2014-07-09 | 四川省惠达药业有限公司 | 一种盐酸头孢吡肟化合物、其制备方法及其药物组合物 |
| BR112018009725A8 (pt) * | 2015-12-10 | 2019-02-26 | Naeja Rgm Pharmaceuticals Ulc | compostos de cefém, sua produção e uso |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4029655A (en) * | 1975-04-11 | 1977-06-14 | Eli Lilly And Company | Method of preparing stable sterile crystalline cephalosporins for parenteral administration |
| JPS55151588A (en) * | 1979-05-14 | 1980-11-26 | Takeda Chem Ind Ltd | Preparation of cephalosporin salt crystal |
| JPS5612397A (en) * | 1979-05-25 | 1981-02-06 | Glaxo Group Ltd | Intermediate for manufacture of cephalosporin antibiotic |
| US4329453A (en) * | 1979-10-02 | 1982-05-11 | Glaxo Group Limited | Cephalosporin antibiotic |
| US4406899A (en) * | 1982-03-04 | 1983-09-27 | Bristol-Myers Company | Cephalosporins |
| CA1213882A (en) * | 1982-03-04 | 1986-11-12 | Jun Okumura | Cephalosporins |
| US4525473A (en) * | 1983-03-30 | 1985-06-25 | Bristol-Myers Company | Cephalosporins |
| US4537959A (en) * | 1984-03-26 | 1985-08-27 | Eli Lilly And Company | Crystalline cephalosporin antibiotic salt |
| US4751295A (en) * | 1984-04-09 | 1988-06-14 | Bristol-Myers Company | Cephalosporin derivatives |
| US4749694A (en) * | 1984-04-26 | 1988-06-07 | Merck & Co., Inc. | Novel lysine esters used as absorption |
| FR2585705B1 (fr) * | 1985-08-05 | 1989-01-13 | Bristol Myers Co | Sels de cephalosporine et compositions injectables |
| US4808617A (en) * | 1985-12-18 | 1989-02-28 | Bristol-Myers Company | Lyophilized or precipitated cephalosporin zwitterion and salt combination |
| US4791196A (en) * | 1986-09-26 | 1988-12-13 | Sankyo Company Limited | Crystalline cephem carboxylic acid addition salt |
-
1988
- 1988-01-19 US US07/144,899 patent/US4910301A/en not_active Expired - Lifetime
- 1988-12-06 YU YU02211/88A patent/YU221188A/xx unknown
-
1989
- 1989-01-12 NZ NZ227605A patent/NZ227605A/en unknown
- 1989-01-13 CZ CS89243A patent/CZ281602B6/cs not_active IP Right Cessation
- 1989-01-13 SK SK243-89A patent/SK281768B6/sk unknown
- 1989-01-16 ES ES8900146A patent/ES2012948A6/es not_active Expired - Fee Related
- 1989-01-16 FI FI890213A patent/FI86854C/sv not_active IP Right Cessation
- 1989-01-17 IT IT8947539A patent/IT1229528B/it active
- 1989-01-17 GR GR890100025A patent/GR1001218B/el not_active IP Right Cessation
- 1989-01-18 GB GB8901073A patent/GB2213819B/en not_active Expired - Lifetime
- 1989-01-18 EG EG2189A patent/EG18749A/xx active
- 1989-01-18 LU LU87432A patent/LU87432A1/fr unknown
- 1989-01-18 DE DE3901359A patent/DE3901359A1/de active Granted
- 1989-01-18 CA CA000588576A patent/CA1298288C/en not_active Expired - Lifetime
- 1989-01-18 FR FR8900553A patent/FR2626003B1/fr not_active Expired - Lifetime
- 1989-01-18 SE SE8900173A patent/SE505258C2/sv not_active IP Right Cessation
- 1989-01-18 NL NL8900111A patent/NL192266C/nl not_active IP Right Cessation
- 1989-01-18 DD DD89325118A patent/DD283397A5/de unknown
- 1989-01-18 PT PT89474A patent/PT89474B/pt not_active IP Right Cessation
- 1989-01-18 DK DK020789A patent/DK162054C/da not_active IP Right Cessation
- 1989-01-18 BE BE8900051A patent/BE1002749A5/fr active
- 1989-01-18 AT AT0008589A patent/AT399878B/de not_active IP Right Cessation
- 1989-01-18 DD DD89333774A patent/DD284807A5/de unknown
- 1989-01-18 ZA ZA89407A patent/ZA89407B/xx unknown
- 1989-01-18 HU HU89185A patent/HU205940B/hu unknown
- 1989-01-18 IE IE14489A patent/IE67447B1/en not_active IP Right Cessation
- 1989-01-18 OA OA59509A patent/OA09227A/xx unknown
- 1989-01-18 KR KR1019890000493A patent/KR950003612B1/ko not_active IP Right Cessation
- 1989-01-19 JP JP1008776A patent/JPH0725768B2/ja not_active Expired - Lifetime
- 1989-01-19 AU AU28623/89A patent/AU615509B2/en not_active Expired
-
1992
- 1992-07-24 SG SG754/92A patent/SG75492G/en unknown
- 1992-09-24 HK HK722/92A patent/HK72292A/xx not_active IP Right Cessation
-
1993
- 1993-05-14 CY CY1663A patent/CY1663A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI86854B (fi) | Foerfarande foer framstaellning av kristallina hydrat av cefalosporinsalt. | |
| KR840001776B1 (ko) | 세프타지딤 펜타하이드레이트의 제조방법 | |
| FI76094C (sv) | Förfarande för framställning av terapeutiskt användbara kristallina 7- (2-(2-aminotiazol-4-yl)-2-syn-metoxiiminoacetamido)-3-((2,3-cyklopente no-1-pyridino)-metyl)-cef-3-em-4-karboxylat-syraadditionssalter | |
| KR930003121B1 (ko) | 세팔로스포린염의 제조방법 | |
| AU621040B2 (en) | Crystallized cephem-acid addition salts, and a process for the preparation thereof | |
| CA1043261A (en) | Cephalosporin-type antibiotic composition | |
| US5244891A (en) | Injectable compositions of cefepime dihydrochloride hydrate | |
| JPH0613525B2 (ja) | 新結晶性セフタジジン、その製造方法および医薬製剤 | |
| US4994451A (en) | Cephalosporin salts and injectable compositions | |
| FI62311C (fi) | Foerfarande foer framstaellning av kristallint natrium- och kaiumcefalexinmonohydrat | |
| US4791196A (en) | Crystalline cephem carboxylic acid addition salt | |
| KR890000787B1 (ko) | 세팔로스포린 유도체 성분의 주사용 또는 외용제의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Owner name: BRISTOL-MYERS SQUIBB COMPANY |
|
| MA | Patent expired |